blisibimod

E2190219 UNEXPLORED

Blisibimod is an experimental monoclonal antibody–based biologic designed to inhibit B-cell activating factor (BAFF) for the treatment of autoimmune diseases such as systemic lupus erythematosus.

Try in SPARQL Jump to: Surface forms Referenced by

All labels observed (1)

Label Occurrences
blisibimod canonical 1

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

BAFF targetOfDrug blisibimod